Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$65.72 - $80.5 $400,892 - $491,050
6,100 Added 89.71%
12,900 $1.04 Million
Q1 2024

May 15, 2024

BUY
$69.39 - $97.64 $471,852 - $663,952
6,800 New
6,800 $542,000

Others Institutions Holding AXSM

About Axsome Therapeutics, Inc.


  • Ticker AXSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,878,000
  • Market Cap $3.73B
  • Description
  • Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...
More about AXSM
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.